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across risk age models
Grunde Wibetoe1*, Joseph Sexton2, Eirik Ikdahl1, Silvia Rollefstad1, George D. Kitas3,6, Piet van Riel4,
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Abstract
Background: In younger individuals, low absolute risk of cardiovascular disease (CVD) may conceal an increased
risk age and relative risk of CVD. Calculation of risk age is proposed as an adjuvant to absolute CVD risk estimation
in European guidelines. We aimed to compare the discriminative ability of available risk age models in prediction of
CVD in rheumatoid arthritis (RA). Secondly, we also evaluated the performance of risk age models in subgroups
based on RA disease characteristics.
Methods: RA patients aged 30–70 years were included from an international consortium named A Trans-Atlantic
Cardiovascular Consortium for Rheumatoid Arthritis (ATACC-RA). Prior CVD and diabetes mellitus were exclusion
criteria. The discriminatory ability of specific risk age models was evaluated using c-statistics and their standard
errors after calculating time until fatal or non-fatal CVD or last follow-up.
Results: A total of 1974 patients were included in the main analyses, and 144 events were observed during follow-
up, the median follow-up being 5.0 years. The risk age models gave highly correlated results, demonstrating R2
values ranging from 0.87 to 0.97. However, risk age estimations differed > 5 years in 15–32% of patients. C-statistics
ranged 0.68–0.72 with standard errors of approximately 0.03. Despite certain RA characteristics being associated
with low c-indices, standard errors were high. Restricting analysis to European RA patients yielded similar results.
Conclusions: The cardiovascular risk age and vascular age models have comparable performance in predicting CVD
in RA patients. The influence of RA disease characteristics on the predictive ability of these prediction models
remains inconclusive.
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Background
Patients with rheumatoid arthritis (RA) have higher risk
of cardiovascular disease (CVD) [1]. Risk algorithms for
the general population lack precision when applied to
RA patients, while validated RA-specific CVD prediction
models are currently lacking [2–5].
Numerous CVD risk prediction models have been de-
veloped and differ in terms of CVD events (fatal or non-
fatal), patient population of interest, and also CVD risk
factors (CVD-RFs) included [6]. In clinical practice, the
decision whether to initiate lipid-lowering therapy or not
is supported by calculating the absolute risk of CVD [7].
Using the Systematic Coronary Risk Evaluation (SCORE)
algorithm, the absolute 10-year risk of a fatal CVD event
can be estimated separately for patients in countries with
low and high risk of CVD [8]. The SCORE algorithm es-
timates CVD risk according to age, sex, and modifiable
CVD-RFs including smoking status, systolic blood pres-
sure (sBP), and total cholesterol (TC). Since high-density
lipoprotein cholesterol (HDL-c) may improve prediction
of CVD, an updated algorithm includes TC to HDL-c ra-
tio [9, 10]. The European League Against Rheumatism
(EULAR) advises to adapt CVD risk prediction models
with a 1.5 multiplication factor to the estimated risk of
CVD for patients with RA [11].
Absolute risk of CVD the next 10 years is largely
driven by age, and younger individuals will thus have a
low calculated risk by SCORE, even in the presence of
high levels of CVD-RFs [12]. Accordingly, a low absolute
10-year risk may conceal a high relative and lifetime risk
of CVD [7]. Risk age may be a favorable supplement for
assessment and communication of CVD risk, and its use
is recommended in the guidelines on CVD prevention
by the European Society of Cardiology (ESC) in addition
to assessment of absolute 10-year risk [7].
The risk age concept estimates the detrimental effects
of CVD-RFs, by comparing the absolute risk of the pa-
tient of interest to the absolute risk in a hypothetical in-
dividual of the same sex with the absence of CVD-RFs (a
non-smoker with sBP of 120mmHg and TC at 4 mmol/
L). Estimated risk age for any given individual may be
similar to his/her true age or far beyond the chronologic
age in presence of high levels of CVD-RFs. If a 40-year-
old has a risk age of 60 years, then he/she has an abso-
lute risk corresponding to a 60-year-old person of the
same sex without CVD-RFs (non-smoker with sBP of
120 mmHg and TC of 4 mmol/L). Currently, two risk
age models based on the SCORE algorithm have been
developed: the cardiovascular risk age and the vascular
age [13, 14].
Recently, we reported that different CVD risk age
models yield highly correlated results, yet differ by 5
years or more in a substantial fraction of RA patients,
suggesting a need for validation of these prediction
models [15]. Our objective was to compare the discrim-
inative ability of cardiovascular risk age and vascular age
calculations in predicting CVD among RA patients. We
also aimed to evaluate the performance of these risk age
models in subgroups of RA patients stratified according
to rheumatic disease related characteristics.
Methods
Study populations
Patients were included from the international consor-
tium, A Trans-Atlantic Cardiovascular Consortium for
Rheumatoid Arthritis (ATACC-RA), which encompasses
11 RA patient cohorts (the UK, Norway, Netherlands,
Sweden, Greece, Spain, the USA, South Africa, Canada,
Mexico (2 cohorts)) [3]. Approval was granted by the
ethical boards/committees at each center. Data were
anonymized and aggregated before analyses.
In the current analyses, we included patients aged 30–
70 years at baseline. Exclusion criteria were prior CVD
and/or diabetes mellitus at baseline in line with Euro-
pean guidelines (as CVD risk prediction is limited to pa-
tients without known prior CVD and/or diabetes
mellitus). For main analyses, we also excluded patients
using lipid-lowering therapy (LLT) and/or antihyperten-
sive treatment (AntiHT) at baseline. In secondary ana-
lyses, we performed analyses on data from European RA
cohorts (subanalyses 1), included RA patients on LLT
and/or AntiHT (subanalyses 2), and performed analyses
on European RA cohorts also including patients on LLT
and/or AntiHT (subanalyses 3).
Demographic and rheumatic disease characteristics
Age, sex, and RA disease-related variables (disease dur-
ation, disease activity score using 28 joint count
(DAS28), rheumatoid factor (RF) and anti-citrullinated
protein antibodies (ACPA), and treatment with glucocor-
ticoids (GC), synthetic and biologic disease-modifying
anti-rheumatic drugs (bDMARDs and sDMARDs)) were
collected at baseline. Recorded CVD-RFs included current
smoking, sBP, TC, and HDL-c; body mass index (BMI),
low-density lipoprotein cholesterol (LDL-c), and triglycer-
ides were also recorded.
Outcomes
The outcome of interest was time to physician-verified
fatal or non-fatal CVD events, including CVD death,
myocardial infarction, stroke, peripheral arterial disease
(with or without revascularization procedures), and cor-
onary revascularization (percutaneous coronary inter-
vention or coronary artery bypass grafting). Patients
were followed from baseline to the time of event or cen-
sored at the time of last follow-up.
Wibetoe et al. Arthritis Research & Therapy           (2020) 22:90 Page 2 of 10
Relative risk calculation
Relative risk of CVD was calculated according to the
relative risk chart, which is included in the 2016 Euro-
pean guidelines on CVD prevention in clinical practice,
in accordance with smoking status as well as total chol-
esterol and systolic blood pressure levels [7].
Risk age estimations using the cardiovascular risk age
model
Cardiovascular risk age was estimated according to the
cardiovascular risk age chart, based on the nearest inter-
vals of sBP (120/140/160/180 mmHg) and TC (4/5/6/7/
8 mmol/L) for males and females, depending on different
chronologic age strata (40/45/50/55/60/65 years) [13].
Risk age estimations using the vascular age model
In contrast, the vascular age calculation was performed
in two steps. First, we estimated 10-year risk of fatal
CVD according to the SCORE algorithms [8, 10]. Then,
we matched calculated 10-year risk to corresponding
risk ages [14]. The vascular age was calculated in four
different ways, corresponding to the four different
SCORE formulas for assessing the 10-year risk of fatal
CVD: using the formula for low-risk countries and the
formula high-risk countries, as well as those with and
without HDL-c.
Statistical analysis
Descriptive data was presented as counts (percentages)
for categorical data and as mean or median for normally
distributed and non-normally distributed data, respect-
ively. The significance level was set at p < 0.05.
Since the cardiovascular risk age model was developed
for patients aged 40–65, ages 30–40 and 65–70 years
were truncated to 40 and 65 years, respectively. Agree-
ment between risk age models was evaluated using R2
from a linear regression model and the frequency of risk
age estimations differing 5 years or more across models.
To validate the CVD risk prediction models, discrim-
ination (e.g., correctly ranking patients who experience
CVD as individuals at higher risk than those who do not
experience CVD) was calculated using concordance sta-
tistics (c-statistics) [16, 17]. Moreover, c-statistics with
standard errors were compared across risk age models
to evaluate which risk age models perform better at
ranking individuals correctly as low- or high-risk indi-
viduals (in which the latter should have shorter observed
time to event). Concordance was also estimated for indi-
vidual centers.
Furthermore, concordance according to sex and base-
line RA disease characteristics was calculated to assess
whether these features influence the risk age model’s
predictive ability. In detail, these RA disease characteris-
tics included (1) disease duration ≤ 1 vs. > 1 year, (2)
disease activity (remission/low disease activity vs. moder-
ate/high disease activity according to DAS28) [18, 19],
(3) seropositivity (RF and/or ACPA positivity), and pres-
ence or absence of anti-rheumatic treatment with (4)
glucocorticoids, (5) methotrexate, (6) sDMARDs in gen-
eral, or (7) bDMARDs. The sampling variability of these
sub-group c-statistics was assessed using standard
errors.
Statistical analyses were conducted using R 3.2.0 (R
Foundation for Statistical Computing, Vienna, Austria)
and STATA version 14.1.
Results
Table 1 presents baseline characteristics of the 1973 RA
patients included in the main analyses.
Seventy-four percent were female, and median (inter-
quartile range) age was 52.0 (44, 59) years. Disease dur-
ation was 0.6 (0.1, 5.8) years, and more than half (61%)
had an RA disease duration of 1 year or less. Overall,
73% were RF positive. There were a substantial number
of patients with moderate (43%) or high (30%) disease
activity according to DAS28. Twenty-four percent were
treated with glucocorticoids, while 10% and 38% were
using bDMARDs and sDMARDs, respectively. About a
third (30%) were current smokers, and 19% were obese
(BMI ≥ 30kg/m2).
The median follow-up time was 5.0 (2.5, 9.1) years. A
total of 144 RA patients experienced CVD events during
the observation period: confirmed myocardial infarction
(n = 64), stroke (n = 33), CVD death (n = 19), peripheral
arterial events (n = 14), and revascularization procedures
(n = 14). Among the patients included in the main ana-
lyses, estimation of risk age was not possible in 338
(17%) and 357 (18%) individuals when using prediction
models without or with HDL-c, respectively, due to
missing data on sBP (n = 114), TC (n = 205), HDL-c (n =
219), and current smoking (n = 119).
The estimated risk of CVD according to different pre-
diction models are presented in Table 2. Calculated risk
age was highest when the cardiovascular risk age model
was applied and, depending on the specific risk age
model used, the median risk age ranged from 56 to 59
years. According to the relative risk table, two thirds of
patients with RA had at least twice the risk of CVD (due
to either smoking and/or elevated sBP/TC levels), com-
pared to individuals with no CVD-RFs, whereas 7–28%
of RA patients would be classified as high-risk individ-
uals (absolute 10-year risk of fatal CVD ≥ 5%) at base-
line, depending on which SCORE algorithm was used
and if the EULAR 1.5 multiplication factor was applied
or not.
The scatter plot (Fig. 1) gives a graphical presentation
of the agreement between estimated risk age according
to the cardiovascular risk age model and the various
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vascular age models. Linear regression analyses, calculating
the correlation between the risk age models, yielded R2
values ranging from 0.87 to 0.97. Moreover, comparison of
cardiovascular risk age and various vascular age models re-
vealed that risk age estimations differed ≥ 5 years in 15–32%
of observations. The most extreme risk age difference was
21 years in which a female non-smoker, aged 69 years, sBP
of 151mmHg and HDL-c and TC of 2.8 and 7.5mmol/L,
respectively, had a cardiovascular risk age of 80 years, and a
vascular age of 59 according to the vascular age model
(using the SCORE HDL-c algorithm for low-risk countries).
Overall, the risk age algorithms had c-indices ranging
from 0.68 to 0.72, with standard errors (SE) around 0.03
(Table 3). The cardiovascular risk age model had the
lowest c-index. Applying the EULAR 1.5 multiplication
factor to the estimated risk do not change the risk rank-
ing of subjects and thereby have no impact on concord-
ance. Table 3 also presents the c-indexes when
stratifying on sex and RA disease related characteristics.
Certain characteristics were associated with low con-
cordance, but standard errors were high. Additional ana-
lyses restricted to only European cohorts and/or
Table 1 Patient characteristics
Main population (n = 1974) Sub-analyses 1 (n = 1543) Sub-analyses 2 (n = 2617) Sub-analyses 3 (n = 1991)
Follow-up time in years, median (IQR) 5 (2.6,9.1) 5 (2.7,10.3) 5 (2.3,7.7) 5 (2.5,8.5)
Age in years, median (IQR) 52.0 (43.7,59.4) 53.1 (45,60.5) 54 (45.5,61) 55.3 (46.8,62)
Females, n (%) 1465 (74%) 1095 (71%) 1955 (75%) 1432 (72%)
Disease duration in years, median
(IQR)
0.6 (0.1,5.8) 0.4 (0,4.3) 0.8 (0.1,7.6) 0.6 (0.1,6)
Rheumatoid factor, n (%) 1437 (73%) 1078 (70%) 1907 (74%) 1392 (70%)
Anti-cyclic citrullinated peptide
antibody, n (%)
1239 (66%) 905 (62%) 1649 (67%) 1177 (63%)
Glucocorticosteroids, n (%) 469 (24%) 345 (22%) 675 (26%) 502 (25%)
Biologic DMARD, n (%) 193 (10%) 149 (10%) 321 (12%) 239 (12%)
Synthetic DMARD, n (%) 722 (38%) 517 (34%) 1056 (43%) 743 (37%)
Methotrexate, n (%) 581 (30%) 365 (24%) 864 (34%) 529 (27%)
DAS 28, mean (SD) 4.2 (1.6) 4.3 (1.5) 4.1 (1.6) 4.2 (1.5)
Remission (< 2.6) 334 (18%) 206 (14%) 491 (20%) 280 (15%)
Low disease activity (2.6, 3.2) 169 (9%) 141 (10%) 234 (9%) 187 (10%)
Moderate disease activity (3.2, 5.1) 810 (43%) 681 (47%) 1051 (42%) 876 (47%)
High disease activity (> 5.1) 566 (30%) 433 (30%) 704 (28%) 540 (29%)
CRP (mg/l), median (IQR) 6.2 (1.4, 18) 8 (2, 21) 6.2 (1.4, 17) 8 (2, 20)
ESR (mm/h), median (IQR) 20 (10, 35.9) 20 (10, 36) 20 (10, 36) 20 (10, 36)
TJC 28, median (IQR) 4 (1, 8) 4 (2, 8) 4 (1, 8) 4 (1, 8)
SJC 28, median (IQR) 5 (2, 9) 5 (2, 9) 4 (1, 9) 5 (2, 9)
Total cholesterol (mmol/l), median
(IQR)
5.2 (4.4, 5.9) 5.3 (4.5, 6.1) 5.2 (4.4, 6) 5.4 (4.6, 6.1)
HDL-c (mmol/l), median (IQR) 1.4 (1.1, 1.7) 1.4 (1.2, 1.7) 1.4 (1.1, 1.7) 1.4 (1.2, 1.7)
LDL-c (mmol/l), median (IQR) 3.1 (2.4, 3.8) 3.2 (2.6, 4) 3.1 (2.4, 3.8) 3.2 (2.6, 3.9)
Triglyceride (mmol/l), median (IQR) 1.2 (0.9, 1.7) 1.2 (0.9, 1.7) 1.2 (0.9, 1.7) 1.2 (0.9, 1.7)
Systolic BP (mm Hg), mean (SD) 134.1 (21.4) 137.7 (21.2) 136.1 (21.8) 139.7 (21.7)
Diastolic BP (mm Hg), mean (SD) 80.1 (10.8) 81.4 (10.5) 80.8 (11) 82.2 (10.7)
BMI (kg/m2), median (IQR) 25.6 (23.0, 28.7) 25.4 (22.9, 28.4) 26.1 (23.4, 29.5) 25.9 (23.3, 29.3)
BMI ≥ 30 kg/m2, n (%) 324 (19%) 226 (17%) 523 (23%) 366 (22%)
Current smokers, n (%) 560 (30%) 497 (34%) 678 (28%) 599 (32%)
IQR inter-quartile range, SD standard deviation, bDMARDs and sDMARDs biologic and synthetic disease-modifying antirheumatic drugs, DAS28 disease activity
score using 28 joint count, CRP C-reactive protein, ESR erythrocyte sedimentation rate, HDL-c high-density lipoprotein cholesterol, sBP and dBP systolic and
diastolic blood pressure. Baseline characteristics describing demographic data, rheumatoid arthritis-related disease characteristics, and cardiovascular risk factors in
rheumatoid arthritis at baseline. Data are also specified on patients who do and do not experience CVD events during follow-up. In subanalyses 1, only European
rheumatoid arthritis cohorts were included. In subanalyses 2, rheumatoid arthritis patients on lipid-lowering therapy and/or antihypertensive treatment were
included. In subanalyses 3, analyses were performed on patients from European rheumatoid arthritis cohorts also including patients on lipid-lowering therapy
and/or antihypertensive treatment
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including patients on LLT and/or AntiHT gave compar-
able results (data not shown). Finally, we evaluated the
concordance of risk models for each center, which re-
vealed wide ranging c-indexes (data not shown). For
centers in which CVD events did not occur during the
observation period, concordance could not be calculated
(data not shown).
Discussion
Using longitudinal data with CVD outcomes from
rheumatic outpatient clinics from the total ATACC-RA
cohort, we have revealed comparable ability of various
risk age models to rank RA patients in terms of time to
CVD events. Interestingly, the cardiovascular risk age
chart, which is based on quite wide CVD-RF intervals
(e.g., sBP 120/140/160/180 mmHg), had only a slightly
lower c-index (0.68) than the other risk age models, indi-
cating comparable performance in correct ranking of
individuals in terms of future CVD risk. Thus, although
risk age estimations frequently differ 5 years or more
[15], their discriminative ability is very similar.
Among the included RA patients, the concordance
was about 0.7 for all risk age models and similar to the
SCORE algorithms they are based on, which had a c-
index of 0.71–0.72. Thus, c-indices were somewhat
lower than what was reported for the general European
population in the original SCORE paper. Conroy et al.
found c-indices of 0.81 and 0.74 for high- and low-risk
countries, respectively [8].
Evaluating risk age models by investigating time to
event and using a composite of CVD events, the cardio-
vascular risk age model and the vascular age models all
had comparable c-statistics around 0.7. In comparison, a
concordance of 0.5 implies a discriminative ability no
better than pure chance, whereas c-statistics ap-
proaching 0.60 to 0.75 are sometimes expressed as
Table 2 Estimated risk age, relative risk, and absolute risk
Risk age All patients
Cardiovascular risk age in years, median (IQR) 59 (48, 69)
Vascular age in years, median (IQR)[SCORE-Hrisk algorithm] 57 (46, 67)
Vascular age in years, median (IQR)[SCORE-Lrisk algorithm] 56 (45, 66)
Vascular age in years, median (IQR)[SCORE-HDL-c-Hrisk algorithm] 58 (49, 67)
Vascular age in years, median (IQR)[SCORE-HDL-c-Lrisk algorithm] 56 (47, 65)
Relative risk
Relative risk of 1, n (%) 562 (34.4)
Relative risk of 2, n (%) 473 (28.9)
Relative risk of 3, n (%) 316 (19.3)
Relative risk of 4, n (%) 124 (7.6)
Relative risk of 5, n (%) 60 (3.7)
Relative risk of 6, n (%) 50 (3.1)
Relative risk of 7, n (%) 32 (2.0)
Relative risk of 8, n (%) 10 (0.6)
Relative risk of 10, n (%) 7 (0.4)
Relative risk of 12, n (%) 2 (0.1)
Individuals with an absolute 10-year risk of fatal CVD ≥ 5%
SCORE-Hrisk algorithm, n (%) 295 (18.0)
SCORE-Lrisk algorithm, n (%) 131 (8.0)
SCORE-HDLc-Hrisk algorithm, n (%) 305 (18.9)
SCORE-HDLc-Lrisk algorithm, n (%) 111 (6.9)
mSCORE-Hrisk algorithm, n (%) 447 (27.3)
mSCORE-Lrisk algorithm, n (%) 248 (15.2)
mSCORE-HDLc-Hrisk algorithm, n (%) 461 (28.2)
mSCORE-HDLc-Lrisk algorithm, n (%) 235 (14.4)
IQR inter-quartile range, SCORE Systematic Coronary Risk Evaluation, Hrisk high-risk country, HDLc high-density lipoprotein-cholesterol, Lrisk low-risk country,
mSCORE modified SCORE using a 1.5 multiplication factor, CVD cardiovascular disease, BP blood pressure, TC total cholesterol. Estimated risk age according to the
cardiovascular risk age and the various vascular age models, relative risk, and absolute risk of cardiovascular disease in RA patients at baseline. Data are also
shown separately for patients who did and did not experience CVD events during follow-up
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demonstration of “possibly helpful discrimination” and
> 0.75 as “clearly useful discrimination” (although this is
a criticized practice) [20].
External validation of the SCORE algorithm, from
which the cardiovascular risk age and vascular age
models are based on and calculated from, respectively,
have revealed wide ranging c-statistics. In a review by
Damen et al., reported c-indices ranged from 0.62 to
0.91 in different European and non-European study pop-
ulations [6]. Comparisons of c-indices across popula-
tions are hampered due to factors such as differences in
age distributions. However, for analyses in these cohorts,
several additional explanations of the observed subopti-
mal concordance are plausible. The SCORE algorithm
was developed for the European population. In our ana-
lyses, European and non-European cohorts were in-
cluded. Additional analyses restricted to data from
European cohorts were performed, but comparable c-
indices were found. We also performed CVD risk
estimations using both algorithms for high- and low-risk
countries. In the main analyses, we pooled data across
centers to increase the numbers and observation time
(total person years at risk), but a limitation is the hetero-
geneity between the various cohorts. There was wide
range of the c-indexes and standard errors across each
unique center included in the analyses.
In RA, inflammatory disease activity, disease duration,
and usage of GCs, sDMARDs, and bDMARDs are all
factors that may influence overall risk of CVD [21–28].
In a recent study, Crowson et al. demonstrated that al-
beit conventional CVD-RFs accounted for half (49%) of
CVD events in RA, high-grade inflammation and RA
characteristics explained about 30% of the CVD risk
[29]. However, the prediction models we evaluated only
assess CVD risk related to conventional CVD-RFs. Fur-
thermore, RA patients without known CVD have high
occurrence of atherosclerotic plaques even in the case of
only moderate estimated absolute risk, justifying the use
Fig. 1 Agreement in estimated risk age by the cardiovascular risk age and vascular age models. Cardiovascular risk age estimations versus
cardiovascular risk age calculations using the SCORE algorithms with (left panels) or without HDL-C (right panels) for high-risk countries (top
panels) and low-risk countries (bottom panels)
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of carotid ultrasound as a supplement in CVD risk
stratification [30].
The latest EULAR recommendations on CVD risk man-
agement underline that rheumatic disease activity should
be controlled to lower overall risk of CVD [11]. RA-
related characteristics may also complicate the interpret-
ation of conventional CVD-RFs. The lipid paradox de-
notes the phenomena in which low lipid levels due to
elevated inflammation is associated with an increased risk
of CVD [31]. Thus, a future RA-specific CVD risk algo-
rithm should possibly weight lipid levels according to the
disease activity. Regarding CVD prediction models, if im-
portant CVD-RFs are left out or not weighted appropri-
ately, then concordance will be impaired.
In this paper, we aimed to evaluate the influence of
RA disease characteristics on the performance of risk
age models in ranking individuals correctly as high(er)-
or low(er)-risk individuals. However, our findings were
inconclusive due to the lack of statistical power resulting
from the small number of participants included and/or
short observation time with few events occurring.
Underreporting of CVD events during the follow-up
time is also possible, especially since RA patients may
suffer from asymptomatic CVD events [32]. The incon-
clusive results on the association of RA disease charac-
teristics and the c-index values due to large standard
errors could have been different with a longer follow-up
time and more participants. In time-to-event analyses,
consideration of informative and interval censoring is
also required. Only data on disease activity and
sDMARD and bDMARD treatment were available at
baseline. Surprisingly, a high rate of RA patients was not
using sDMARDs and bDMARDs at study inclusion. Al-
though this should be considered before extrapolation of
our results to other RA cohorts, this may be partly ex-
plained by that a high rate of RA patients included in
these analyses had short disease duration (explaining
why some were methotrexate naive) and also to differ-
ences across different nations (explaining why some
were bDMARDs naïve). Another limitation to this
multi-center study is the lack to control that BP mea-
surements were conducted similarly. Data on family
Table 3 Discriminatory ability according to stratification by RA disease characteristics
Sex RF ACPA ACPA/RF bDMARDs
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Concordance index (standard error) presenting the discriminative ability in ranking individuals who do or do not experience cardiovascular events correctly as
high and low risk. Values are presented for various risk age models, including vascular age estimations derived from application of different Systematic Coronary
Risk Evaluation algorithms with or without use of high-density lipoprotein-cholesterol (HDLc) for high- and low-risk countries (H-risk and L-risk). Individuals were
also stratified according to sex, rheumatoid factor (RF), and anti-cyclic citrullinated peptide antibody (ACPA) positivity, use of biologic or synthetic disease
modifying antirheumatic drugs (bDMARDs and sDMARDs), disease activity score using 28-joint count (DAS28), and duration of rheumatoid arthritis (RA)
Significance and innovations
• Risk age estimations have been advocated in current guidelines for CVD prevention
• The two proposed risk age models have not been validated
• Our results indicate comparable performance of risk age models in rheumatoid arthritis patients
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history of premature CVD were also lacking. Among eli-
gible patients, estimation of risk age were not possible in
338–357 individuals when using prediction models with-
out or with HDL-c, respectively, due to missing data on
sBP (n = 114), TC (n = 205), HDL-c (n = 219), and
current smoking (n = 119).
There are also limitations with c-index calculation
since it reports concordance based on ranks and not on
the magnitude of risk differences. Consequently, in the
case of very similar and only slightly different risk ages
across subjects, the CVD prediction model’s discrimin-
atory ability will be impaired. Moreover, concordance
only describes one feature regarding the predictive abil-
ity of a risk model. Calibration, a comparison of the
number of expected events to the number of observed
events, is another important property regarding valid-
ation of prediction models [33]. However, in contrast to
models predicting absolute risk, calibration cannot be
performed in prediction models using the risk age
concept.
The risk age models we have validated are derived
from the SCORE algorithms which calculate absolute
risk of fatal CVD. In the original SCORE publication, the
authors argued that developing a CVD prediction model
based on non-fatal CVD events are prone to errors due
to misclassification. Non-fatal events are also of clinical
importance, and it has been suggested to convert
SCORE with a multiplier to estimate fatal and non-fatal
events [7, 34]. However, Jørstad et al. found that the ra-
tio of risk of fatal to fatal plus non-fatal CVD was largely
dependent on age and sex and, consequently, a fixed
multiplication factor was not applicable [35]. Since risk
age communicates the detrimental effects of modifiable
CVD-RFs on overall CVD risk and/or life expectancy, it is
an attractive concept, also informing patients on the bene-
fit of optimizing CVD-RFs. In the review by Groenewegen
et al., it is argued that the perspicuous risk age concept
might improve communication about CVD risk and pos-
sibly patient adherence to CVD preventive strategies (e.g.
lifestyle changes and/or cardio-protective medication)
[12]. CVD risk assessment is especially important in RA
due to the high prevalence of modifiable CVD-RFs [36–
38]. However, whether the risk age is an intuitive concept
and if it has incremental value beyond absolute and rela-
tive risk calculation needs further evaluation.
To our knowledge, this is the first study comparing
the discriminative ability of the risk age models pro-
posed for use as supplements to CVD risk evaluation in
the ESC guidelines for the general population [7, 12].
Not surprisingly, our study supports the notion that risk
age models perform similarly to the SCORE algorithms
in ranking individuals correctly as high or low risk of
CVD events. Despite that risk age estimations frequently
differ 5 years or more, the current risk age models based
on SCORE perform almost equivalently in terms of
concordance.
Conclusions
Albeit different CVD risk age algorithms yield marked
disparities in a substantial proportion of patients, the
cardiovascular risk age and vascular age models have
comparable performance in predicting CVD events in
RA patients. Furthermore, their concordance is equiva-
lent to the SCORE algorithms they are derived from.
The influence of RA disease characteristics on the pre-
dictive ability of these prediction models remains incon-
clusive. Further evaluation is also required to assess
whether use of risk age estimations in clinical practice is
beneficial for CVD-RF reduction and, ultimately, preven-
tion of CVD events.
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